TG Therapeutics Inc (NASDAQ:TGTX)’s share price was down 6.3% during trading on Thursday . The stock traded as low as $7.63 and last traded at $7.68, approximately 1,758,215 shares were traded during mid-day trading. An increase of 8% from the average daily volume of 1,624,737 shares. The stock had previously closed at $8.20.
A number of analysts have weighed in on TGTX shares. ValuEngine lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. B. Riley started coverage on TG Therapeutics in a research report on Wednesday, November 27th. They set a “buy” rating and a $12.00 target price for the company. Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a report on Tuesday, November 12th. Finally, BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $12.95.
The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.00 and a current ratio of 1.00. The company’s 50 day moving average price is $7.22 and its two-hundred day moving average price is $6.94.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.33). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 2,411.79% and a negative net margin of 123,130.93%. On average, sell-side analysts expect that TG Therapeutics Inc will post -1.96 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. Millennium Management LLC grew its position in shares of TG Therapeutics by 6,258.4% during the 3rd quarter. Millennium Management LLC now owns 7,521,910 shares of the biopharmaceutical company’s stock worth $42,235,000 after buying an additional 7,403,611 shares in the last quarter. BlackRock Inc. increased its stake in shares of TG Therapeutics by 19.5% during the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock valued at $45,883,000 after buying an additional 866,572 shares during the period. Vanguard Group Inc. increased its stake in shares of TG Therapeutics by 19.7% during the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock valued at $34,955,000 after buying an additional 665,380 shares during the period. Sofinnova Investments Inc. increased its stake in shares of TG Therapeutics by 258.5% during the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock valued at $10,911,000 after buying an additional 909,573 shares during the period. Finally, Camber Capital Management LP bought a new stake in shares of TG Therapeutics in the second quarter valued at about $8,650,000. 48.63% of the stock is owned by institutional investors and hedge funds.
About TG Therapeutics (NASDAQ:TGTX)
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Recommended Story: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.